Country websites:


The medical device and therapy related information on this website is aimed exclusively at healthcare professionals.

Not all products are cleared or available for sale in all countries.

By clicking on the button "Accepted and Confirmed" you assure that you have taken note of this information and that you are a healthcare professional.

Brain and neurology

Neurology-related clinical indications

Brain indications

Many important neurological diseases are accompanied with an autoimmune pathophysiology, so making it difficult to treat using conventional approaches. Therapeutic apheresis has shown to be a valuable and important treatment option in neurological diseases such as Guillain-Barré syndrome, myasthenia gravis and other peripheral conditions. There has also been great interest in progress made using extracorporeal techniques to treat idiopathic encephalitis and a subset of patients with multiple sclerosis. Furthermore, a new field of research has begun evaluating the scope for therapeutic apheresis to improve the cognitive functions of patients with vascular dementia.


Related products

1. Instruction for use (IFU) LIGASORB®, Art. Nr. F00001564, 35840318 / Mar.–May 2016
2. Dogan et al, Immunoadsorption therapy in autoimmune encephalitides. Neurology 26 Feb. 2016; 3(2): 207. Retreived from
3. Dorst et al, (2016) Immunoadsorption with regenerating columns in treatment of steroid-refractory relapse in multiple sclerosis and optic neuritis. Multiple Sclerosis Journal (Foster City) 3: 178.
4. Schneidewind et al, Immunoadsorption: A new therapeutic possibility for multiple sclerosis? Transfusion Science Mar. 1998; 19 Suppl: 59–63.
5. Karczewski et al, Agonistic autoantibodies to the α(1) -adrenergic receptor and the β(2) -adrenergic receptor in Alzheimer's and vascular dementia. Scandinavian Journal of Immunology May 2012; 75(5): 524–30.
6. Hempel et al, Immunoadsorption of agonistic autoantibodies against α1-adrenergic receptors in patients with mild to moderate dementia. Therapeutic Apheresis and Dialysis Oct. 2016; 20(5): 523–29.
7. Zinman et al, A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy. Transfusion and Apheresis Science Nov. 2005; 33(3): 317-24.
8. Rech et al, Remission of demyelinating polyneuropathy with immunoadsorption, low dose corticosteroids and anti-CD20 monoclonal antibody. Therapeutic Apheresis and Dialysis June 2008; 12(3): 205–8.
9. Baggi et al, Effect of IgG immunoadsorption on serum cytokines in MG and LEMS patients. Journal of Neuroimmunology 15 September 2008; 201/202: 104–10.
10. Schwartz et al, Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: The sixth special issue. Journal of Clinical Apheresis 28 July 2013; 28(3): 145–284.